Rene Russo's Insider Trades & SAST Disclosures
Rene Russo's most recent trade in Xilio Therapeutics Inc was a trade of 190,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on April 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Rene Russo.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2025 | 190,000 | 190,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 638,000 | 638,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 44,250 | 244,883 | - | - | Common Stock | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 44,250 | 132,750 | - | - | Restricted Stock Units | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 474,000 | 474,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 177,000 | 177,000 | - | - | Restricted Stock Units | |
| Xilio Therapeutics Inc | Rene Russo | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2023 | 700,000 | 700,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 350,000 | 350,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, CEO and President, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2021 | 50,041 | 50,041 | - | - | Stock Option (right to buy) | |
| Invivyd Inc | Rene Russo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2021 | 35,593 | 35,593 | - | - | Stock Option (Right to Buy) | |
| X4 Pharmaceuticals Inc | Rene Russo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| X4 Pharmaceuticals Inc | Rene Russo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 3,427 | 3,427 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges